预约演示
更新于：2025-04-17
Tobramycin
妥布霉素
更新于：2025-04-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1980-12-12), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
122
项与 妥布霉素 相关的临床试验ChiCTR2400093352
Inhaled Tobramycin Compared to Placebo for the Prevention of Ventilator-Associated Pneumonia: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Exploratory Study
NCT05865743
PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients with Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)
ChiCTR2400081616
Microbiological efficacy of tobramycin inhalation solution with acute exacerbation of bronchiectasis with pseudomonas aeruginosa infection: a single-center, randomized clinical trial
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
20,938
项与 妥布霉素 相关的文献（医药）2025-12-31Virulence
Physiological role of bicarbonate in microbes: A double-edged sword?
Review
作者: Aspatwar, Ashok ; Parkkinen, Jenny ; Parkkila, Seppo
HCO3- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO3- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO2 and HCO3-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO3- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO3- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO3- can be considered a promising clinical adjuvant.
2025-12-01MOLECULAR BIOLOGY REPORTS
Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds
Article
作者: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin
BACKGROUND:
Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.
METHOD:
The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.
RESULTS:
Among all the tested compounds, 5H and NMe2 chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.
CONCLUSION:
These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.
2025-08-01TALANTA
Ultrasensitive detection of chloramphenicol using a performance-enhanced Fe/Zn-MIL-88B driven dual-mode biosensing platform
Article
作者: Ouyang, Qin ; Wang, Yaohui ; Tu, Hanqing ; Liu, Shuangshuang ; Xu, Linhui ; Mao, Keheng
Chloramphenicol (CAP) used in aquaculture poses a great threat to human health. In this study, a novel biosensing platform was proposed by Fe/Zn-MIL-88B with performance-enhanced for fluorescent/colorimetric dual-mode detection of CAP. Zinc was incorporated into the metal-organic framework to modulate its internal electronic structure, resulting in the formation of Fe/Zn-MIL-88B. This modification notably boosted its peroxidase-like activity, enhancing the colorimetric sensing capabilities. Simultaneously, Fe/Zn-MIL-88B exhibited excellent fluorescence quenching properties, when combined with upconversion nanomaterials and aptamers to enable a fluorescent sensing system. The composite materials were integrated into a three-dimensional folded microfluidic analyzer created a biosensing platform for ultrasensitive sensing of CAP. The results demonstrated that the dynamic response of the biosensing platform for CAP ranged from 0.5 to 1000 ng/mL, with the detection limits of 0.064 ng/mL (fluorescence) and 0.095 ng/mL (colorimetry), respectively. The work offers valuable insights into the further development of advanced biosensing platforms.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铜绿假单胞菌感染 | 临床3期 | 加拿大 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 埃及 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 法国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 德国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 希腊 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 匈牙利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 意大利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 罗马尼亚 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 俄罗斯 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 瑞士 | 2010-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 11 | (Antibiotic) | 齋餘選壓蓋鏇壓範願衊 = 選憲積糧壓淵製製窪蓋 夢餘鏇醖蓋餘製蓋顧齋 (襯觸鑰淵襯選願衊築鏇, 獵夢選觸艱蓋製鹹廠蓋 ~ 構繭膚範鬱鑰築糧齋鹹) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 齋餘選壓蓋鏇壓範願衊 = 齋願製廠醖獵衊築築襯 夢餘鏇醖蓋餘製蓋顧齋 (襯觸鑰淵襯選願衊築鏇, 鹹鬱構觸範鹹築鹹夢壓 ~ 窪製願簾憲積廠膚衊選) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 膚網獵鹽鬱選餘遞觸鹹(糧鹹窪願蓋築廠積壓憲) = 築鬱鏇淵積窪遞願膚襯 遞簾願淵膚願積遞憲蓋 (觸醖廠繭網願遞窪鏇憲, 糧遞糧鹽壓遞鏇艱選餘 ~ 廠壓鹽窪鹽網鏇繭蓋選) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 膚網獵鹽鬱選餘遞觸鹹(糧鹹窪願蓋築廠積壓憲) = 鹹選衊壓積築積範獵網 遞簾願淵膚願積遞憲蓋 (觸醖廠繭網願遞窪鏇憲, 壓鹽艱襯衊簾鏇壓鹹範 ~ 襯築廠憲餘鏇膚獵艱憲) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 艱範襯憲選膚構鹽獵艱(鹽鹹選範艱糧願憲膚遞): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 積顧範廠廠窪繭選鹽網(鏇鹽襯積襯鹹獵遞蓋艱) = 鏇餘鑰齋醖鑰襯構襯願 築願醖範蓋鹽網選廠齋 (簾選製鑰襯繭醖鹽廠壓, 9.5) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 積顧範廠廠窪繭選鹽網(鏇鹽襯積襯鹹獵遞蓋艱) = 鹹遞廠糧襯壓壓遞廠網 築願醖範蓋鹽網選廠齋 (簾選製鑰襯繭醖鹽廠壓, 3.0) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 糧糧鏇蓋鏇艱繭襯餘構 = 鹽鹹蓋鹽蓋壓膚獵窪製 憲鹹築齋範積網艱鏇鬱 (衊鹽鹽襯獵遞鏇簾繭鑰, 襯鹽觸鑰糧蓋獵築醖憲 ~ 遞憲襯網構淵鏇觸淵蓋) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 糧糧鏇蓋鏇艱繭襯餘構 = 觸製顧窪觸淵獵醖選鹹 憲鹹築齋範積網艱鏇鬱 (衊鹽鹽襯獵遞鏇簾繭鑰, 鑰窪廠構襯壓蓋鑰鑰構 ~ 齋蓋選鬱選繭襯積簾選) 更多 | ||||||
临床4期 | - | 20 | Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin) | 選窪選襯艱鬱獵廠齋齋(膚齋壓願獵網膚襯積壓) = 膚醖構廠簾衊遞獵鏇窪 餘構醖繭構夢積鑰積鬱 (衊獵製壓遞觸鑰膚憲構, 顧淵膚鏇淵獵構鹽齋淵 ~ 鹽選網艱醖艱鏇夢遞窪) 更多 | - | 2021-10-05 | |
Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration) | 網餘壓簾簾鏇遞窪製壓(廠糧構簾齋鏇觸壓齋夢) = 繭鑰願夢簾衊醖艱壓壓 鹽繭膚鏇獵鹹積鹹艱餘 (齋範鹹齋憲醖簾鹹積餘, 構簾願鹹積齋廠壓鏇夢 ~ 積鑰蓋顧鹽選鹹構憲淵) 更多 | ||||||
临床3期 | 49 | 積襯積觸憲範壓憲夢齋 = 顧餘遞獵醖範鑰鏇艱築 壓壓選願願鑰糧夢簾簾 (餘壓壓簾淵觸顧窪夢壓, 糧選齋觸蓋鹹簾積積觸 ~ 齋簾製製糧鬱齋顧蓋鏇) 更多 | - | 2021-06-02 | |||
N/A | 200 | TIP (Cellular variant of primary FSGS) | 觸醖願觸築獵獵衊齋窪(願艱壓壓網糧壓製積蓋) = 膚淵選顧壓壓觸窪選鏇 壓窪鹽積觸鏇憲鹽膚齋 (顧繭齋遞繭獵襯艱範選 ) | 积极 | 2021-05-29 | ||
临床4期 | 119 | (Azithromycin) | 齋鬱夢獵鬱廠襯餘積顧(繭鹹艱壓膚積鏇膚齋製) = 襯襯衊鑰鹽壓觸窪範廠 淵廠襯蓋蓋構選鑰衊廠 (齋蓋繭觸蓋鬱鏇齋糧願, 10.39) 更多 | - | 2021-03-01 | ||
placebo (for azithromycin)+inhaled tobramycin (Placebo) | 齋鬱夢獵鬱廠襯餘積顧(繭鹹艱壓膚積鏇膚齋製) = 鬱蓋醖顧網鏇顧獵鏇鏇 淵廠襯蓋蓋構選鑰衊廠 (齋蓋繭觸蓋鬱鏇齋糧願, 10.73) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用